Exelixis, Inc. EXEL
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. 10-K, Item 1
- Employees
- 1,077
- Headquarters
- Alameda, CA
- CEO
- Michael Morrissey
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $2.3B through the costs to a net profit of $782.6M · income statement of the 10-K
EXEL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
12 new risk paragraphs. 10-K filed Feb 10, 2026 against Feb 11, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +8.1% ($265.4M to $286.9M) vs revenue +7.0% ($2.2B to $2.3B), +1.1 pts apart
-
Cash from operations $884.3M vs net income $782.6M (FY ending Jan 2, 2026)
-
Inventory -3.1% ($22.4M to $21.7M) vs revenue +7.0% ($2.2B to $2.3B), -10.1 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No longer listed: Table of C o n t e n t s. Same as last year: Net product revenues
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
12 paragraphs in Risk Factors that were not in the 10-K filed Feb 11, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
Concern over access to and affordability of pharmaceutical products continues to spur debate and action by U.S. federal and state government authorities in an effort to contain healthcare costs. Such proposals and actions include: •use of mandated discounts, rebates, restrictive formularies, or other reference-based price controls, such…
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
In addition, the current U.S. administration has indicated that it plans to pursue additional policies aimed at lowering prescription drug costs. For example, on May 12, 2025, the current administration published an executive order that expressed support for equalizing the prices paid for drugs in the United States and other developed…
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
On March 17, 2025, April 24, 2025, and May 27, 2025, we received notice letters (collectively, Notices) from the West Virginia Board of Pharmacy (WV Board) of complaints filed against us for purported violations of laws related to distribution of drugs to 340B facilities (West Virginia Code § 60A-8-6a (WV Statute)). The WV Statute…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.6B | $1.8B | $2.2B | $2.3B |
| Net income | $182.3M | $207.8M | $521.3M | $782.6M |
| Operating cash flow | $362.6M | $333.3M | $700.0M | $884.3M |
| Free cash flow | $334.9M | $292.9M | $671.5M | $875.8M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.3B ▲ 7.0% in FY2025$782.6M ▲ 50.1% in FY2025$875.8M ▲ 30.4% in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KOct 29, 2026Quarterly results 8-K item 2.02
-
10-QOct 29, 2026Quarterly report (10-Q) period ended Oct 2, 2026
About the company
Exelixis, Inc., Alameda, CA · from the 10-K filed Feb 10, 2026
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications.
- Headquarters
- Alameda, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- January 1
- Last results
- Oct 29, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had 1,077 employees, representing a 6" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 10, 2026 (open at SEC), compared with the 10-K filed Feb 11, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.